Heatwurx (PCSA) Competitors $0.22 +0.03 (+14.55%) As of 03:52 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock PCSA vs. LSB, TLPH, DWTX, AEON, NLSP, CLRB, CHRO, KPRX, TSBX, and BMRAShould you be buying Heatwurx stock or one of its competitors? The main competitors of Heatwurx include LakeShore Biopharma (LSB), Talphera (TLPH), Dogwood Therapeutics (DWTX), AEON Biopharma (AEON), NLS Pharmaceutics (NLSP), Cellectar Biosciences (CLRB), Chromocell Therapeutics (CHRO), Kiora Pharmaceuticals (KPRX), Turnstone Biologics (TSBX), and Biomerica (BMRA). These companies are all part of the "pharmaceutical products" industry. Heatwurx vs. Its Competitors LakeShore Biopharma Talphera Dogwood Therapeutics AEON Biopharma NLS Pharmaceutics Cellectar Biosciences Chromocell Therapeutics Kiora Pharmaceuticals Turnstone Biologics Biomerica Heatwurx (NASDAQ:PCSA) and LakeShore Biopharma (NASDAQ:LSB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings, media sentiment and valuation. Which has more volatility and risk, PCSA or LSB? Heatwurx has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500. Comparatively, LakeShore Biopharma has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Which has preferable valuation & earnings, PCSA or LSB? Heatwurx has higher earnings, but lower revenue than LakeShore Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHeatwurxN/AN/A-$11.85M-$3.08-0.07LakeShore Biopharma$80.82MN/A-$61.09MN/AN/A Do analysts prefer PCSA or LSB? Heatwurx presently has a consensus target price of $2.00, indicating a potential upside of 800.90%. Given Heatwurx's stronger consensus rating and higher possible upside, analysts clearly believe Heatwurx is more favorable than LakeShore Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heatwurx 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00LakeShore Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor PCSA or LSB? In the previous week, Heatwurx had 6 more articles in the media than LakeShore Biopharma. MarketBeat recorded 8 mentions for Heatwurx and 2 mentions for LakeShore Biopharma. Heatwurx's average media sentiment score of 0.73 beat LakeShore Biopharma's score of 0.00 indicating that Heatwurx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Heatwurx 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive LakeShore Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is PCSA or LSB more profitable? LakeShore Biopharma's return on equity of 0.00% beat Heatwurx's return on equity.Company Net Margins Return on Equity Return on Assets HeatwurxN/A -319.56% -232.40% LakeShore Biopharma N/A N/A N/A Do insiders and institutionals believe in PCSA or LSB? 91.9% of Heatwurx shares are held by institutional investors. Comparatively, 52.6% of LakeShore Biopharma shares are held by institutional investors. 9.6% of Heatwurx shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryHeatwurx beats LakeShore Biopharma on 9 of the 12 factors compared between the two stocks. Get Heatwurx News Delivered to You Automatically Sign up to receive the latest news and ratings for PCSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PCSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PCSA vs. The Competition Export to ExcelMetricHeatwurxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.64M$2.37B$5.47B$8.92BDividend YieldN/A1.78%5.24%4.04%P/E Ratio-0.078.9227.0520.14Price / SalesN/A501.68380.7693.83Price / CashN/A21.7726.2128.59Price / Book0.484.528.005.58Net Income-$11.85M$31.26M$3.16B$248.40M7 Day Performance11.00%6.11%3.84%6.13%1 Month Performance-26.15%5.75%3.04%7.78%1 Year Performance-86.21%1.24%34.26%20.95% Heatwurx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PCSAHeatwurx3.6437 of 5 stars$0.22+14.6%$2.00+800.9%-88.8%$2.64MN/A-0.0720LSBLakeShore Biopharma0.3485 of 5 stars$0.99-0.4%N/AN/A$9.26M$80.82M0.00773News CoveragePositive NewsGap UpTLPHTalphera1.6068 of 5 stars$0.46+2.7%$5.00+979.9%-50.7%$9.25M$650K-1.0319DWTXDogwood Therapeutics1.1598 of 5 stars$4.60-4.2%$10.00+117.4%N/A$9.17MN/A-0.255Positive NewsAEONAEON Biopharma3.3607 of 5 stars$0.79-5.5%$360.00+45,371.8%-98.9%$8.95MN/A4.405NLSPNLS PharmaceuticsN/A$2.27-7.0%N/A+1,101.1%$8.78MN/A0.006Analyst UpgradeCLRBCellectar Biosciences3.3014 of 5 stars$4.80flat$375.00+7,712.5%-93.3%$8.69MN/A-0.2210Gap DownCHROChromocell TherapeuticsN/A$1.34+6.3%N/A-89.1%$8.69MN/A-1.084Gap UpHigh Trading VolumeKPRXKiora Pharmaceuticals2.2816 of 5 stars$2.81-1.4%$10.00+255.9%-38.8%$8.68MN/A-0.9710TSBXTurnstone Biologics1.5715 of 5 stars$0.37+0.9%$0.45+23.3%-83.7%$8.37MN/A-0.1382BMRABiomerica0.376 of 5 stars$3.40+4.0%N/A-2.5%$8.32M$5.41M-1.4760 Related Companies and Tools Related Companies LakeShore Biopharma Alternatives Talphera Alternatives Dogwood Therapeutics Alternatives AEON Biopharma Alternatives NLS Pharmaceutics Alternatives Cellectar Biosciences Alternatives Chromocell Therapeutics Alternatives Kiora Pharmaceuticals Alternatives Turnstone Biologics Alternatives Biomerica Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PCSA) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heatwurx Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Heatwurx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
